Press Releases

Read about the latest Hoth Therapeutics
technology, research, investor updates
and much more.

Jan 4, 2022

Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the...

Dec 21, 2021

Hoth Therapeutics Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis

Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it submitted an Orphan Drug Designation Request to the US Food and Drug Administration...

Dec 8, 2021

Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has...

View All

Our Purpose

Founded in 2017, Hoth Therapeutics, Inc. was formed as a global platform to commercialize innovative and proprietary therapeutics. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders.

Home Page Icons